This analysis uses 2023 Medicare claims for traditional Medicare, Medicare Advantage encounter data, and Part D prescription drug event data to estimate the total number of Medicare beneficiaries with obesity or overweight, the number of Part D enrollees who met the Bridge eligibility criteria in 2023, and those who met the Bridge clinical criteria but who also had diagnoses recorded in claims or encounter data that would qualify for Part D coverage of GLP-1s (type 2 diabetes, OSA, or MASH) or who had a GLP-1 Part D-covered prescription during the year, either of which would make them ineligible for Bridge (see Methods)
People who want to take care of their skin from within for a more youthful appearance
weekly), the duration of GLP-1 RAs use, the indication of use (diabetes mellitus vs
Las emulsiones aceite en agua (cremas) tambin se utilizan, especialmente para tratamientos que combinan el GHK-Cu con otros activos liposolubles
Endocrinologists now note that continued low-dose use can prevent the cycle of loss and regain that frustrates many patients
GLP-1s arent safe for everyone